Completed PHASE2 INTERVENTIONAL 4-arm NCT00630539

A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women

Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo

Sponsor: Hormos Medical

Conditions Atrophy Vaginal Diseases

Interventions Ospemifene 15 mg Ospemifene 30 mg Ospemifene 5 mg Placebo

Updated 6 times since 2017 Last updated: May 21, 2013 Started: Aug 31, 2007 Primary completion: Jan 31, 2008 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00630539, this PHASE2 trial focuses on Atrophy and Vaginal Diseases and remains completed. Sponsored by Hormos Medical, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hormos Medical
QuatRx Pharmaceuticals
Shionogi

Data source: Shionogi Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.